Navigation Links
Savara Closes Series A Financing Round
Date:6/9/2009

- Funds Raised Will Be Used to Expand Technology into New Pulmonary Markets -

AUSTIN, Texas, June 9 /PRNewswire/ -- Savara Pharmaceuticals, a biotechnology inhalation drug delivery company, today announced that it has closed its Series A financing round.

The majority of Savara's existing investors participated in the round, which was made up of biotechnology industry veterans and successful business leaders. Savara will utilize the funds to continue development of its NanoCluster technology in the dry powder therapeutics market and expand into nebulizer and propellant markets.

"I'm excited that we exceeded our entire Series A fund raising goal in just a few weeks," said Rob Neville, Savara's Executive Chairman. "The funds from our seed round allowed us to validate our technology across multiple drug classes, which led to several partnerships with large pharmaceutical companies. We've assembled a world class team and are ready to pursue the numerous opportunities ahead of us."

Savara has the option to complete a second tranche of the Series A round later this year if additional funds are needed.

The key parameter to improving the efficacy of pulmonary products depends on being able to dial-in particles sizes in the range of one to three microns. The Savara NanoCluster technology has this capability without the need for novel excipients and benefits from a highly efficient manufacturing process. These NanoClusters are modeled after naturally occurring aerosols, which are highly effective in reaching the peripheral lung.

About Savara

Savara Pharmaceuticals, (www.savarapharma.com) develops next generation pulmonary drug delivery solutions using its NanoCluster formulation technology. Dry powder and nebulizer-based medicines are formulated directly from active drug ingredients, requiring no carrier particles and little or no excipients. The aerodynamics of NanoCluster formulations are fully customizable from one to seven microns enabling high drug concentrations at specific regions of the lung, independent of the rate or depth of breath. Savara expects that NanoCluster's unique features will produce numerous patient benefits including reduced dosage, enhanced efficacy, improved safety and increased tolerability, as well as greater patient convenience. Savara's NanoCluster technology is currently available for evaluation and licensing.

CONTACT: Ian M. Stone for Savara Pharmaceuticals, +1-619-528-2220, ian.stone@russopartnersllc.com


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Response Biomedical Closes $12.65 million Unit Offering
2. Swine Flu Closes Three Schools in NYC
3. Swine Flu Closes 3 Schools in NYC
4. Aethlon Medical Discloses New HIV/AIDS Treatment Data
5. ASA May Day - Stung By Exposure of Watergate-like Public Record Deletions, American Society of Anesthesiologists Closes Access to Website Newsletter
6. Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes
7. PhotoThera Closes $50 Million Financing, Announces New President and Chief Executive Officer
8. ProAssurance Closes PICA Transaction
9. Conseco Closes Amendment to Credit Facility
10. ReGear Life Sciences Closes $2.5 Million in Series A Financing Following $1M Investment by Stonewood Capital Management, Inc.
11. GetWellNetwork Closes $10 Million Financing, Eight Hospitals Choose PatientLife System(R) for Unparalleled Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
Breaking Medicine Technology: